Corcept Therapeutics (CORT) Projected to Post Earnings on Monday

Corcept Therapeutics (NASDAQ:CORT) is expected to announce its Q1 2025 earnings results before the market opens on Monday, May 5th. Analysts expect Corcept Therapeutics to post earnings of $0.17 per share and revenue of $177.93 million for the quarter. Corcept Therapeutics has set its FY 2025 guidance at EPS.

Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $0.26 earnings per share for the quarter, missing the consensus estimate of $0.37 by ($0.11). Corcept Therapeutics had a net margin of 22.35% and a return on equity of 24.54%. The firm had revenue of $181.89 million for the quarter, compared to analysts’ expectations of $200.12 million. On average, analysts expect Corcept Therapeutics to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Corcept Therapeutics Price Performance

CORT stock opened at $73.23 on Wednesday. The company has a current ratio of 3.70, a quick ratio of 3.64 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $7.73 billion, a price-to-earnings ratio of 58.12 and a beta of 0.15. Corcept Therapeutics has a 12-month low of $22.60 and a 12-month high of $117.33. The firm’s 50-day moving average price is $65.11 and its two-hundred day moving average price is $59.55.

Insider Buying and Selling at Corcept Therapeutics

In other Corcept Therapeutics news, insider Sean Maduck sold 100,000 shares of the stock in a transaction that occurred on Monday, March 31st. The shares were sold at an average price of $100.54, for a total value of $10,054,000.00. Following the transaction, the insider now directly owns 85,622 shares in the company, valued at approximately $8,608,435.88. This trade represents a 53.87 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Daniel N. Swisher, Jr. sold 2,200 shares of the firm’s stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $68.08, for a total value of $149,776.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 163,124 shares of company stock worth $15,117,614. Company insiders own 20.50% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on CORT shares. StockNews.com lowered Corcept Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, February 28th. Truist Financial lifted their target price on shares of Corcept Therapeutics from $76.00 to $150.00 and gave the company a “buy” rating in a research note on Monday, March 31st. Canaccord Genuity Group upped their target price on Corcept Therapeutics from $130.00 to $142.00 and gave the stock a “buy” rating in a report on Tuesday, April 1st. Piper Sandler raised their target price on Corcept Therapeutics from $128.00 to $131.00 and gave the company an “overweight” rating in a research note on Thursday, April 3rd. Finally, HC Wainwright lifted their price target on shares of Corcept Therapeutics from $115.00 to $150.00 and gave the company a “buy” rating in a research report on Monday, March 31st. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $143.25.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.